A Comparison of Two DAAs Used in a Unique Model of Care to Treat Hepatitis C Infections in New Jersey
2024

Comparing Two Treatments for Hepatitis C

Sample size: 769 publication Evidence: moderate

Author Information

Author(s): Slim Jihad, Paul Bellafiore, Tempalski Barbara, Rosmarin-DeStefano Corey, Leyden Kevin, Torres Juan, Duprey Sheena, Levaggi Emily

Primary Institution: NYMC, St. Michaels Medical Center, Newark, New Jersey, USA

Hypothesis

Is there a difference in efficacy between glecaprevir/pibrentasvir and sofosbuvir/velpatasvir in treating hepatitis C in a unique care model?

Conclusion

Both treatment regimens showed high completion rates and efficacy without significant differences in outcomes.

Supporting Evidence

  • 90.4% of patients completed treatment.
  • 8% of patients treated with glecaprevir/pibrentasvir were lost to follow-up compared to 11% for sofosbuvir/velpatasvir.
  • Both treatment regimens were well tolerated with no patients discontinuing due to adverse events.

Takeaway

This study looked at two medicines for hepatitis C and found they work just as well when given to people in a special program that helps those with drug problems.

Methodology

This was a prospective observational study comparing the efficacy of two medications in treating hepatitis C among patients in a mobile clinic setting.

Potential Biases

The study may have underestimated adverse events due to reliance on passive patient reporting.

Limitations

The study's generalizability is limited due to its single-center, observational design.

Participant Demographics

The median age of participants was 40 years, with a gender distribution of 63% male and 37% female.

Statistical Information

P-Value

<.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/ofid/ofae645

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication